TDNA — T. Rowe Price Biotech ETF

Data updated: 2026-07-24

TDNA — T. Rowe Price Biotech ETF. Global (incl. US) Health Care Equity · 0.55% expense ratio. Holdings, fees, performance and SEC filings.

TDNA Fund Overview

TDNA — T. Rowe Price Biotech ETF is a US ETF managed by T. Rowe Price Exchange-Traded Funds, Inc., categorised as Global (incl. US) Health Care Equity. ABC INVEST provides holdings, performance, costs, cashflows, risk data, prospectus documents and SEC filings, sourced from SEC filings.

TDNA Investment Objective and Strategy

T. Rowe Price Biotech ETF describes its objective and strategy as follows, from its latest prospectus filed with the SEC by T. Rowe Price Exchange-Traded Funds, Inc..

Investment objective

The fund seeks to provide long-term capital appreciation.

Principal investment strategy

The fund normally invests at least 80% of its net assets (plus any borrowings for investment purposes) in the securities of biotechnology companies. The fund defines biotechnology companies as companies engaged in health care innovations, such as developing new and effective therapies to treat and cure disease through the use of living cells. The fund references the MSCI GICS (Global Industry Classification Standard) biotechnology and pharmaceuticals industries to identify such companies. Any derivatives that provide exposure to the investment focus suggested by the fund’s name, or to one or more market risk factors associated with the investment focus suggested by the fund’s name, are counted (as applicable) toward compliance with the fund’s 80% investment policy. As a fundamental policy, the fund will concentrate (invest more than 25% of its net assets) in biotechnology companies.

The majority of the fund will be invested in equity securities, such as common stocks. While most assets are typically invested in U.S. common stocks, the fund may invest in foreign stocks in keeping with its investment objective. The fund uses fundamental, bottom-up analysis and may invest in companies of any market capitalization. The advisor prioritizes healthcare innovation, identifying companies that are advancing technologies that could meaningfully advance the care of individuals with disease. There is a special focus on companies developing: (i) new platform technologies, e.g., pioneering new drug technologies or novel therapeutic targets, (ii) approaches which expand the impact of existing technologies, or (iii) companies which capitalize on novel insights into human biology/disease.

The fund will invest in companies across different stages of drug development, from preclinical drug discovery companies to commercial stage companies; across distinct therapeutic modalities (such as DNA/RNA-based medicines and cell therapies); and across different therapeutic areas (such as cancer

TDNA Costs and Fees

TDNA costs about $55 per $10,000 invested per year in fund expenses.

  • Net expense ratio: 0.55%
  • Gross expense ratio: 0.55%

TDNA Debt Constituents

No individual debt constituents are reported in T. Rowe Price Biotech ETF's latest SEC N-PORT filing.

TDNA Prospectus and SEC Filings

Official T. Rowe Price Biotech ETF filings on SEC EDGAR — prospectus, portfolio holdings and annual reports.

Related Funds

Related funds tracked on ABC INVEST:

Data Sources

ABC INVEST compiles this page from public filings made to the U.S. Securities and Exchange Commission (SEC) through EDGAR: portfolio holdings and monthly cashflows from Form N-PORT, expenses and returns from fund prospectuses (Form 485BPOS) and the SEC DERA Risk/Return Summary data sets, annual data from Form N-CEN, and shareholder reports from Form N-CSR.